Clinical trials: Malaria, Uncomplicated
Plasmodium Falciparum Malaria
Comparative Evaluation of the Safety and the Efficacy of 2 Antimalarials Depending on HIV Status
The purpose of this study is to determine the safety and efficacy of sulfadoxine-pyrimethamine (SP) versus artemether-lumefantrine (Coartem) when administered to HIV+ and HIV- patients with uncomplicated P. falciparum malaria.
- Trial name
- NCT00304980
- Testing
- ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE
- Where
- Zambia
- Volunteers
- 3,000 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Malaria, Falciparum
Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa
The primary objective is to confirm the hypothesis that azithromycin plus chloroquine is non-inferior to mefloquine for the treatment of symptomatic, uncomplicated malaria due to P. falciparum.
- Trial name
- NCT00082576
- Testing
- Azithromycin/Chloroquine, Mefloquine
- Where
- 6 sites in Ghana, Mali and 2 more
- Volunteers
- 238 people
- Sponsor
- Pfizer
Malaria
Safety and Efficacy of Maytenus Senegalensis for the Treatment of Uncomplicated Malaria
Antimalarial Herbal medicine known as Maytenus senegalensis will be evaluated for its safety, tolerability and efficacy among Tanzanian male adults aged 18 to 45 years.
- Trial name
- MALHERBAL (NCT04944966)
- Testing
- Maytenus Senegalensis
- Where
- Tanzania
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Ifakara Health Institute
Plasmodium Falciparum Malaria
Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria.
Artemether-lumefantrine has been used in Tanzania as first-line treatment for uncomplicated malaria since 2007. Nonetheless, a report of increased proportion of patients with parasitaemia on day 1 following treatment with…
- Trial name
- ALE (NCT02089841)
- Testing
- Artemether-lumefantrine
- Where
- Tanzania
- Volunteers
- 140 people
- Sponsor
- Richard Mwaiswelo
Malaria
Lapdap and Coartemether for Uncomplicated Malaria
Lapdap (chlorproguanil-dapsone) is an affordable and effective drug, but patients with glucose-6-phosphate dehydrogenase (G6PD) A- deficiency are more susceptible to the haemolytic effects of the dapsone component of Lapdap…
- Trial name
- NCT00118794
- Testing
- Chlorproguanil-dapsone (Lapdap), Lumefantrine-artemether (Coartemether )
- Where
- The Gambia
- Volunteers
- 1,200 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Accute Falciparum Malaria
Artemether-lumefantrine Resistance Monitoring in Children With Uncomplicated Plasmodium Falciparum Malaria in Mali
Background: Malaria is a disease caused by a parasite. People get malaria if they are bitten by an parasite-infected mosquito. A drug called artemether-lumefantrine (AL) can treat malaria.
- Trial name
- NCT02645604
- Where
- Mali
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium Falciparum Malaria
Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria
The purpose of this study is to determine the efficacy and safety of imatinib in combination with dihydroartemisinin plus piperaquine in the treatment uncomplicated P. falciparum malaria in adult male patients.
- Trial name
- MIM (NCT02614404)
- Testing
- Imatinib combination therapy, Dihydroartemisinin-piperaquine
- Where
- Vietnam
- Volunteers
- 15 people
- Sponsor
- HuLow
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)
This was Cohort B2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07235033)
- Testing
- KAE609, SoC (Coartem), KLU156
- Where
- 3 sites in Côte d’Ivoire, Gabon and 1 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Falciparum Malaria, Uncomplicated Malaria
Phase II Dose Ranging Study of Artesunate
The purpose of this study is to compare four regimens using US FDA GMP intravenous artesunate for the treatment of uncomplicated Plasmodium falciparum malaria to identify the most effective treatment regimen as determined by…
- Trial name
- NCT00459615
- Testing
- Artesunate for Injection
- Where
- 2 sites in Kenya, Thailand
- Volunteers
- 120 people
- Sponsor
- U.S. Army Office of the Surgeon General
Malaria
Efficacy of Amodiaquine in the Treatment of Uncomplicated Falciparum Malaria in Young Children of Burkina Faso
Design: Single-centre Indication: Malaria caused by Plasmodium falciparum Objectives: To determine and compare the efficacy of AQ treatment in young children with uncomplicated falciparum malaria in the rural and the urban study…
- Trial name
- NCT00261222
- Testing
- Amodiaquine
- Where
- Burkina Faso
- Volunteers
- 120 people
- Sponsor
- Heidelberg University
Oral Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria
Evaluation of Fosmidomycin and Piperaquine in the Treatment of Acute Falciparum Malaria
The objective of this study is to explore the role of fosmidomycin and piperaquine as non-artemisinin-based combination therapy for acute uncomplicated Plasmodium falciparum when administered over three days.
- Trial name
- FOSPIP (NCT02198807)
- Testing
- Fosmidomycin-Piperaquine
- Volunteers
- 100 people
- Sponsor
- Jomaa Pharma GmbH
Uncomplicated Malaria
Malaria Therapeutic Efficacy Study, Rwanda
WHO recommends that Therapeutic Efficacy Studies (TES) for 1st and 2nd line antimalarial medicines should be routinely carried out and data made available for decision-making due to the threat of emergence and spread of…
- Trial name
- NCT04767217
- Testing
- artemether-lumefantrine (ALN), dihydroartemisinin-piperaquine (DHA-PPQ)
- Where
- 3 sites in Rwanda
- Volunteers
- 528 people
- Sponsor
- Jhpiego
Uncomplicated Plasmodium Falciparum Malaria
Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial
Background: Artemisinin resistance has emerged in parts of Southeast Asia, and there are reports in Africa of reduced susceptibility of Plasmodium falciparum parasites against artemisinin-based combination therapy (ACT).
- Trial name
- 3ACT (NCT05764746)
- Testing
- Artemether-lumefantrine and Amodiaquine Drug Combination, Artemether-lumefantrine then Artesunate amodiaquine, Artemether-lumefantrine
- Where
- 2 sites in Tanzania
- Volunteers
- 384 people
- Sponsor
- Muhimbili University of Health and Allied Sciences
Malaria, Falciparum
Assessing the Efficacy of Four Drug Combinations as the Next First-line Therapy for Uncomplicated Malaria in Malawi
Sulfadoxine-pyrimethamine (SP) is the current first-line treatment for uncomplicated malaria in Malawi. The malaria parasite P. falciparum has developed resistance to this drug so that the drug is much less effective than in…
- Trial name
- NCT00164710
- Testing
- sulfadoxine-pyrimethamine, amodiaquine plus sulfadoxine-pyrimethamine, amodiaquine plus artesunate
- Where
- 3 sites in Malawi
- Volunteers
- 365 people
- Sponsor
- Centers for Disease Control and Prevention
Plasmodium Vivax Malaria
Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV)
The current treatment recommendations for P. vivax in pregnant and non-pregnant individuals are to use chloroquine; in non-pregnant patients this is followed by primaquine to prevent relapse.
- Trial name
- PAACT-PV (NCT01107145)
- Testing
- Mefloquine- Artesunate, Artemether-Lumefantrine, Chloroquine
- Where
- 3 sites in Brazil
- Volunteers
- 16 people
- Sponsor
- Centers for Disease Control and Prevention
Drug Resistant Malaria Due to Plasmodium Falciparum
P. Falciparum Resistance to Artemisinin in Vietnam
At the end of 2012, the Institute of Tropical Medicine in collaboration with National Institute of Malariology Parasitology and Entomology (NIMPE) conducted a study in Quang Nam province, central Vietnam, to assess the efficacy…
- Trial name
- NCT02604966
- Testing
- Artesunate (AS) group, DHA - PPQ group
- Where
- Vietnam
- Volunteers
- 120 people
- Sponsor
- National Institute of Malariology, Parasitology and Entomology, Vietnam
Pregnancy Complicated by Malaria as Antepartum Condition
Efficacy,Safety and Tolerability of Dihydroartemisinin-Piperaquine for Uncomplicated Malaria in Pregnancy in Ghana
Malaria in pregnancy poses enormous public health challenges, contributing to significant maternal and infant deaths yearly. Adverse outcomes include maternal anaemia and low birthweight.
- Trial name
- DHAPPQ/MIP (NCT01231113)
- Testing
- artesunate-amodiaquine, Dihydroartemisinin-piperaquine
- Where
- Ghana
- Volunteers
- 417 people
- Sponsor
- Kwame Nkrumah University of Science and Technology
Malaria, Falciparum
Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi
Sulfadoxine-pyrimethamine is the current first-line therapy for uncomplicated malaria in Malawi. Significant resistance of the P.
- Trial name
- NCT00164359
- Testing
- Amodiaquine plus artesunate, chlorproguanil-dapsone plus artesunate
- Where
- 3 sites in Malawi
- Volunteers
- 212 people
- Sponsor
- Centers for Disease Control and Prevention
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria
This is Cohort A1 of the Platform study (NCT05750628) to evaluate the efficacy and safety of INE963 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07235020)
- Testing
- INE963
- Where
- 6 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Uncomplicated Plasmodium Falciparum Malaria
Extended Duration Artemether-lumefantrine Treatment for Malaria in Children
This project determines the pharmacokinetic/pharmacodynamic (PK/PD) of an extended artemether-lumefantrine (AL) dosing regimen in HIV-infected children on efavirenz (EFV)-based antiretroviral therapy (ART) that is designed to…
- Trial name
- EXALT (NCT03453840)
- Testing
- Artemether-lumefantrine
- Where
- 2 sites in Uganda
- Volunteers
- 305 people
- Sponsor
- University of California, San Francisco